MedTrace Logo

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

NCT04833036 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-04-06

No results posted yet for this study

Summary

The primary endpoint is to evaluate the progression-free survival (PFS).

Conditions

Interventions

DRUG

Irinotecan

180 mg/m2, ivgtt d1，q2w

DRUG

cetuximab

500 mg/m2, ivgtt d1，q2w

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-01-31
Completion
2022-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833036 on ClinicalTrials.gov